A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to evaluate i) the effect of multiple doses of vosoritide and ii) the effect of the therapeutic dose of vosoritide compared to human growth hormone (hGH), in children with idiopathic short stature (ISS).

Clinical Trial Description

Following a minimum 6 month observational period in which baseline growth is assessed, participants in the vosoritide and placebo groups will complete a minimum of 6 months of randomized treatment (maximum of 6 months of placebo treatment), followed by open-label treatment with vosoritide until they reach near-final adult height, or at least 16 years of age for females or 18 years of age for males, whichever comes later. Participants randomized to the hGH group will receive open-label hGH for a minimum of 4 years. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06382155
Study type	Interventional
Source	BioMarin Pharmaceutical
Contact
Status	Not yet recruiting
Phase	Phase 2
Start date	September 2024
Completion date	December 2036

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05894876` - A Study of the Genetic Basis of Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
Completed	`NCT01246219` - Short Stature Related Distress	Phase 4
Completed	`NCT00965484` - Genotropin Study Assessing Use of Injection Pen	Phase 3
Completed	`NCT00710307` - Epidemiology Study on Insulin-like Growth Factor-1 in Children With Idiopathic Short Stature (EPIGROW Study)
Completed	`NCT01248416` - Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature	Phase 3
Completed	`NCT01504802` - Pharmacodynamics of CNP During Growth Hormone Treatment	N/A
Completed	`NCT00488124` - Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin	Phase 2
Withdrawn	`NCT01438801` - Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)	Phase 4
Recruiting	`NCT06309979` - A Study to Assess Growth in Children With Idiopathic Short Stature
Terminated	`NCT00121875` - Study to Identify Markers of Insulin Resistance During Growth Hormone Treatment for Short Stature	Phase 4
Not yet recruiting	`NCT05858606` - Multidisciplinary Evaluation and a Genome-wide Analysis in a Cohort of Idiopathic Short Stature Patients	N/A
Active, not recruiting	`NCT04020913` - Skeletal Muscle Effects of GH in Boys
Completed	`NCT01401244` - Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers	Phase 1
Recruiting	`NCT02973061` - The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents
Completed	`NCT01778023` - Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature	Phase 3
Recruiting	`NCT01604395` - Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children
Active, not recruiting	`NCT00840944` - A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height	Phase 4
Completed	`NCT01070173` - Ghrelin Levels in Children With Poor Growth	N/A
Completed	`NCT01543867` - Safety and Efficacy of Long-term Somatropin Treatment in Children	N/A
Recruiting	`NCT04798690` - Long-term Safety and Effectiveness of Growtropin®-II Treatment in Children With Short Stature